Methylene Blue for Cognitive Dysfunction in Bipolar Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00214877|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : April 1, 2008
While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine.
Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.
|Condition or disease||Intervention/treatment||Phase|
|Bipolar Disorder||Drug: Methylene Blue||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder|
|Study Start Date :||November 2003|
|Actual Study Completion Date :||October 2007|
- Young Mania Rating Scale
- Hamilton Depression Rating Scale (HAM-D), 17-item version Hamilton Rating Scale for Anxiety (HAM-A).
- Clinical Global Impression Scale CGI-BP (41)
- Affective Morbidity Index (42)
- California Verbal Learning Task and a process dissociation task. Two tasks will focus on selective attention, negative priming and inhibition of return tasks.
- A visual backward masking task that has been well studied in patients with BD will be used.
- Trails B will be administered as a test of executive function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214877
|Canada, Nova Scotia|
|CDHA- QE II Health Sciences Centre|
|Halifax, Nova Scotia, Canada, B3H-2E2|
|St. Joseph's Healthcare|
|Hamilton, Ontario, Canada, L8N 3K7|
|Principal Investigator:||Martin Alda, MD FRCPC||Dalhousie University|